CHRS Coherus BioSciences Inc.

Coherus BioSciences to Participate at Upcoming September Investor Conferences

Coherus BioSciences to Participate at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

  • Citi's 2023 18th Annual BioPharma Conference in Boston on Wednesday, September 6, 2023, including participation in an I-O Panel Discussion at 3:30 p.m. EDT.
  • 2023 Wells Fargo Healthcare Conference in Boston on Thursday, September 7, 2023 for 1x1 meetings only.
  • H.C. Wainwright 25th Annual Global Investment Conference in New York on September 12-13, 2023 for a fireside chat-format presentation on Tuesday, September 12, 2023 at 1:30 pm EDT.

A live audio webcast and an archive of the presentations from the Citi and HCW conferences will be available on the investors’ page of the Coherus website at .

Coherus Contact Information:

Marek Ciszewski, SVP Investor Relations



EN
01/09/2023

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Pro...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent b...

August 7, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Report Second Quarter 2025 Financial Results on Au...

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of t...

July 31, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Completes Strategic Transformation to Coherus Oncology, Focusi...

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and ...

May 30, 2025 1 EN
Free Trial
CHRS Coherus BioScie...

Coherus Biosciences Inc: 1 director

A director at Coherus Biosciences Inc sold 99,988 shares at 0.739USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

CHRS COHERUS BIOSCIENCES INC.
05/29/25 May 29, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Announces Clinical Collaboration with STORM Therapeutics to Ev...

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) – First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, ...

May 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch